Literature DB >> 30470723

Diagnosis of Attenuated Mucopolysaccharidosis VI: Clinical, Biochemical, and Genetic Pitfalls.

Filippo Pinto E Vairo1,2,3, Erin Conboy3, Carolina Fischinger Moura de Souza4, Amie Jones5, Sarah S Barnett6, Eric W Klee1,2,3,6, Brendan C Lanpher7.   

Abstract

Mucopolysaccharidosis type VI (MPS VI) is a clinically heterogeneous lysosomal disease, which can be divided into 2 main categories on the basis of age of onset and severity of symptoms. The diagnosis of the attenuated form is often delayed given subtle facial features rather than the typical coarse facial features of the classic form. Here, we discuss the difficulties in establishing the diagnosis of MPS VI on the basis of the report of 4 individuals. The most common signs and symptoms in our series were bone abnormalities and hip pain as initial manifestations and cardiac changes detected after follow-up studies. On the basis of our cohort and others worldwide, awareness of attenuated forms of MPS VI should be increased particularly among general practitioners, pediatricians, rheumatologists, orthopedists, ophthalmologists, and cardiologists. Moreover, these health care providers should be aware of the technical aspects involved in the molecular and biochemical diagnosis process so that they are aware how diagnostic errors may occur.
Copyright © 2018 by the American Academy of Pediatrics.

Entities:  

Mesh:

Year:  2018        PMID: 30470723     DOI: 10.1542/peds.2018-0658

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  4 in total

Review 1.  Precision Medicine for Lysosomal Disorders.

Authors:  Filippo Pinto E Vairo; Diana Rojas Málaga; Francyne Kubaski; Carolina Fischinger Moura de Souza; Fabiano de Oliveira Poswar; Guilherme Baldo; Roberto Giugliani
Journal:  Biomolecules       Date:  2020-07-26

2.  Disease burden, management patterns and multidisciplinary clinical approaches for patients with MPS IVA and VI in selected Latin American Countries.

Authors:  Villarreal M Solano; Claudia Yazmín Cossío Mandujano; Carmen Amor Avila-Rejon; Victor Hugo Espin; Hector Paul Quintero Montaño
Journal:  Mol Genet Metab Rep       Date:  2021-05-25

3.  Estimated prevalence of mucopolysaccharidoses from population-based exomes and genomes.

Authors:  Pâmella Borges; Gabriela Pasqualim; Roberto Giugliani; Filippo Vairo; Ursula Matte
Journal:  Orphanet J Rare Dis       Date:  2020-11-18       Impact factor: 4.123

Review 4.  Mucopolysaccharidosis Type VI, an Updated Overview of the Disease.

Authors:  Francesca D'Avanzo; Alessandra Zanetti; Concetta De Filippis; Rosella Tomanin
Journal:  Int J Mol Sci       Date:  2021-12-15       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.